Acurx Pharmaceuticals, Inc.
ACXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736243
No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Acurx Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 25 | 1 | 22 | −2 |
| Shares | 1.21M | 27.5K | 1.27M | +87.4K (+7.4%) |
| Value | $2.71M | $61.9K | $2.41M | −$240.6K (−9.1%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 28,535 | $54.2K | 0.00% |
| StoneX Group Inc. | 17,800 | $33.8K | 0.00% |
Sold out (4)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Cambridge Investment Research Advisors, Inc. | 10,000 | $23.0K |
| UBS Group AG | 881 | $1.98K |
| Citadel Advisors LLC | 64 | $144 |
| Royal Bank of Canada | 132 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 27,503 | $61.9K |